Literature DB >> 3921381

Defective renal water excretion in nephrotic syndrome: the relationship between renal water excretion and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading.

E B Pedersen, H Danielsen, M Madsen, T Jensen.   

Abstract

An oral water load of 20 ml (kg body wt)-1 was given to seventeen patients with the nephrotic syndrome and fifteen healthy control subjects. Diuresis (D), free water clearance (CH2O), plasma concentrations of arginine vasopressin (AVP), angiotensin II (AII) and aldosterone (Aldo) were determined before and 3 times during the first 4 h after loading. In the nephrotic syndrome D was significantly lower 1-2 h after loading than in the control subjects, predominantly due to a lower CH2O (2.61 and 7.01 ml min-1 (medians), P less than 0.01). Creatinine clearance and the maximum increase in CH2O were significantly correlated in patients with the nephrotic syndrome (rho = 0.721, n = 17, P less than 0.01) and the control subjects (rho = 0.596, n = 15, P less than 0.01). AVP was reduced in both groups during loading, but AVP was clearly elevated in the patients with the nephrotic syndrome when compared to the control subjects both before (3.0 and 1.9 pmol 1(-1), P less than 0.01) and during loading. There was a significantly negative correlation between CH2O and AVP in both groups. AII and Aldo were reduced during loading, but the levels were the same in the patients and in the control group, and AII and Aldo were not correlated to CH2O. It is concluded that patients with the nephrotic syndrome excrete an oral water load more slowly than healthy control subjects, and that this phenomenon partly is due to reduced glomerular filtration rate and partly to increased AVP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921381     DOI: 10.1111/j.1365-2362.1985.tb00139.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

1.  New approaches in treatment of hyponatremia.

Authors:  R K Menon
Journal:  Indian J Pediatr       Date:  1985 Sep-Oct       Impact factor: 1.967

2.  Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.

Authors:  Masaki Shimizu; Sayaka Ishikawa; Yusuke Yachi; Masahiro Muraoka; Yuko Tasaki; Hidenori Iwasaki; Mondo Kuroda; Kazuhide Ohta; Akihiro Yachie
Journal:  Pediatr Nephrol       Date:  2013-11-19       Impact factor: 3.714

Review 3.  The non-immunosuppressive management of childhood nephrotic syndrome.

Authors:  James McCaffrey; Rachel Lennon; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2015-11-10       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.